Systematic Review Confirms GLP-1 Agonists as Potent Obesity Treatments

The global obesity epidemic continues to pose a significant public health challenge, driving increased risks for numerous comorbidities like type 2 diabetes, cardiovascular disease, and certain cancers. While lifestyle interventions are foundational, many individuals require pharmacological support to achieve and maintain clinically meaningful weight loss. This systematic review aimed to comprehensively evaluate the efficacy and safety of approved weight loss drugs, with a specific focus on the newer class of GLP-1 receptor agonists, to guide clinical practice and future research.

The systematic review confirmed that GLP-1 receptor agonists are highly effective for weight loss in individuals with obesity. Across numerous clinical trials, these medications consistently demonstrated significant reductions in body weight, with semaglutide (at its highest approved dose) showing an average weight loss of 15-17% from baseline, and liraglutide achieving 5-10% weight reduction. The most impactful finding was the consistent and substantial weight loss achieved by GLP-1 agonists, often exceeding 10% of body weight, which is clinically significant for improving obesity-related comorbidities. Beyond weight loss, the review highlighted improvements in glycemic control (reducing HbA1c by 1.0-2.0% in patients with type 2 diabetes) and cardiovascular risk factors, including reductions in systolic blood pressure by 3-5 mmHg. Common adverse events were primarily gastrointestinal, such as nausea, vomiting, and diarrhea, reported by 70-80% of patients, though these were generally mild to moderate and transient, leading to discontinuation rates of typically less than 10%.